Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract: Fusers, printing apparatuses and methods of fusing toner on media are disclosed. An embodiment of a fuser for heating media includes a fuser roll including an outer portion having a first outer surface; a voltage source connected to the outer portion and adapted to supply voltage to the outer portion to heat the first outer surface; a pressure roll having a second outer surface; and a nip between the first and second outer surfaces. The first and second outer surfaces are adapted to contact a medium at the nip.

Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.

Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.

Abstract: Fusers, printing apparatuses and methods of fusing toner on media are disclosed. An embodiment of a fuser for heating media includes a fuser roll including an outer portion having a first outer surface; a voltage source connected to the outer portion and adapted to supply voltage to the outer portion to heat the first outer surface; a pressure roll having a second outer surface; and a nip between the first and second outer surfaces. The first and second outer surfaces are adapted to contact a medium at the nip.

Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract: Compounds of Formula I wherein R1, A, R2, n, R3, m, R4, R5 and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract: Compounds of Formula I wherein R1, A, R2, R3, R4, R5, R8, n, m, q and r are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract: Nicotinic acetylcholine receptor ligands of Formula I wherein X, n, R1 and R2 are as described in the specification, diastereoisomers, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing, and methods for using the same.

Abstract: Compounds of Formula I: wherein A1, A2, D and E are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.

Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.

Abstract: Compounds of Formula I: wherein R1, R2, R3, R4, R5 Ar1 and X are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.

Abstract: Compounds of Formula II wherein R1, A, R2, R3, R4, R5, R8, n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

Abstract: Compounds having the formula (I) pharmaceutical compositions containing them and their methods of use for the treatment of neurological disorders related to amyloid ? protein production and neurological disorders such as Alzheimer's disease. These compounds inhibit ? secretase and thereby inhibit the production of amyloid ? protein, thereby acting to prevent the formation of neurological deposits of amyloid protein.

Abstract: This invention pertains to a method and apparatus for thermally developing a photosensitive element. The photosensitive element includes a composition layer capable of being partially liquefied upon heating. Heating the layer causes one or more organic compounds in the layer to form a vapor. Oxidation of the vapor forms carbon dioxide and water vapor and reduces the need to manage waste streams containing the organic compounds.

Abstract: Compounds of Formula I or Formula II wherein R1, X and Ar are as described in the specification, pharmaceutically-acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, especially for treatment of conditions associated with reductions in nicotinic transmission.

Abstract: An automated computer-controlled method and apparatus for measuring the quality or fineness of a pigment dispersion sample, comprising placing the pigment dispersion at the deep end of the tapered path of a Hegman gage block, placing the Hegman gage block in a holder in a motorized drawdown device that draws the scraper along the length of the tapered path at an angle and to at a contact pressure and at a controlled rate, thereby creating a tapered film sample of paint whose thickness tapers from a maximum thickness of 100 micrometers to a minimum thickness of zero. An illuminator assembly illuminates the sample with a substantially collimated light source at an intensity level and the light reflected from the sample is collected by a lens onto a photodetector array in a digital camera. After a time interval the camera acquires an image of the sample.

Abstract: A flow cell for measuring the color properties of a liquid flowing therethrough using interrogating radiation at a predetermined wavelength has a thin partition mounted in spaced relationship between both a window and a base of the cell. The partition and the window define an air cavity therebetween. The spacing between the partition and the window is such that evanescent coupling of radiation reflected from the liquid into the material of the window is prevented. The cell has a pressurized fluid inflow channel and a pressurized fluid outflow channel formed therein. Each of the inflow and outflow channels communicates with the air cavity. The inflow and outflow channels are sized to pass a pressurized fluid, such as pressurized air, through the air cavity such that, in use, the spaced relationship between the partition and the window is maintained by pressurized fluid in the air cavity.

Abstract: A system utilizing the flow cell of the present invention includes a reflectance mode spectrophotometer positioned with respect to the flow cell or a probe. Either the flow cell or the probe has a thin partition mounted in spaced relationship with respect to a transparent window. The partition has a predetermined index of refraction and has a thickness dimension that is less than that of the window. The spacing between the partition and the window is such that evanescent coupling of radiation reflected from the liquid into the material of the window is prevented. The spectrophotometer is directs interrogating radiation toward a liquid flowing through the sample chamber and responds to interrogating radiation reflected from the liquid to produce an electrical signal representative of a color property thereof.

Abstract: A flow cell for measuring the color properties of a liquid flowing through the flow cell using interrogating radiation at a predetermined wavelength has a thin partition mounted in spaced relationship between both a window and a base of the cell. The partition has a predetermined index of refraction and has a thickness dimension that is less than that of the window. The spacing between the partition and the window is such that evanescent coupling of radiation reflected from the liquid into the material of the window is prevented. Typically, this spacing is a distance not less than three (3) times the predetermined maximum wavelength in the wavelength range of interrogating radiation. A plurality of spacer elements may be disposed in the air cavity to maintain the spaced relationship between the partition and the window. The flow cell has a liquid supply passage and a liquid removal passage formed therein.